Nomogram predicting overall survival of stage IIIB non‐small‐cell lung cancer patients based on the SEER database
Abstract Purpose We aimed to evaluate the prognostic value of stage IIIB non‐small‐cell (NSCLC) lung cancer patients and to construct a nomogram to effectively predict their overall survival (OS). Methods In total, 4323 patients with stage IIIB NSCLC diagnosed between 1975 and 2018 were selected fro...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | The Clinical Respiratory Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/crj.13660 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Purpose We aimed to evaluate the prognostic value of stage IIIB non‐small‐cell (NSCLC) lung cancer patients and to construct a nomogram to effectively predict their overall survival (OS). Methods In total, 4323 patients with stage IIIB NSCLC diagnosed between 1975 and 2018 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Multiple prognostic factors were combined to construct a nomogram for predicting OS of patients with stage IIIB NSCLC. The discrimination and calibration of the nomogram were evaluated by C‐indexes and calibration curves. The nomogram was evaluated for predictive ability using receiver operating characteristic (ROC) curves, decision curve analysis curve (DCA), and clinical impact curve (CIC). Results The nomogram was built on data of 4323 patients with stage IIIB NSCLC and consisted of the following prognostic factors: age, race, sex, primary labeled, pathology, T stage, whether to receive surgery, whether to receive radiotherapy, and whether to receive chemotherapy. The C‐index in the training and validation sets for the nomogram was 0.672 (95% CI: 0.661–0.683) and 0.675 (95% CI: 0.656–0.694), respectively. According to scores of the nomogram, patients in the complete set, validation set, and training set were classified into two risk groups, low risk and high risk. Conclusions We developed the first validated nomogram to estimate the OS of patients with stage IIIB NSCLC. The nomogram was based on nine prognostic factors and provided an individualized risk estimate of 3‐year and 5‐year OS survival in patients with stage IIIB NSCLC. |
|---|---|
| ISSN: | 1752-6981 1752-699X |